Prostatic Artery Embolization Market Size, Share, Growth, Sales, Trade, Shipment, Export Value And Volume With Sales And Pricing Forecast By 2028

Global Prostatic Artery Embolization Market: Overview

Wellness and medical education of men is an important segment within the domain of global healthcare. Prostatic health and disease are amongst the most critical issue surrounding men’s health. September has been declared as the ‘National Prostate Health Month’ across North America. GPs across the US and Canada make efforts to break stigmas around prostate health during this month. Hence, the global prostatic artery embolization market is expected to expand in size and volume of revenues in the years to come.

Majority of the initiatives around prostatic health are aimed at managing and preventing the incidence of prostate cancer. However, prostatic artery embolization, despite being noncancerous, has gathered attention from the masses due to these initiatives.

Sound prostatic health is important for men to lead congenial and healthy lifestyles. The relationship of prostatic health with the mental health of men has been considered by several medical practitioners. Most men fall victim to prostatic diseases and disorders due to contempt and negligence. Doctors and GPs are emphasizing on the need to address prostatic issues with a high level of urgency.

A report on the prostatic artery embolization market uncovers several legible dynamics related to market growth. The global prostatic artery embolization market can be segmented along the following lines: type, application, and region.

Global Prostatic Artery Embolization Market: Notable Developments

As men’s healthcare becomes a key segment of the medical fraternity, the global prostatic artery embolization market is undergoing several key developments.

• Mentice Group is delving into the modern ways of diagnosing and screening prostate diseases. The company revealed the importance of PAE procedures in prostatic artery embolization. Mentice’s PAE software offers real-time training to radiologists for better diagnosis of prostatic disorders. The global prostatic artery embolization market could invite new investments through the development of PAE-based systems and software.

• Siemens’ ‘Healthineers’ department approved of the use of catheters for delivery of embolic material during prostatic artery embolization market. This factor has played a key role popularising PAE procedures across various healthcare facilities. As researchers develop a bridge between surgery and medical therapy, the market is set to foray into new dimensions of growth.

Other notable players in the global prostatic artery embolization market are:

• Tampa General Hospital
• UNC Health Care
• Henry Ford
• Spire Healthcare

Global Prostatic Artery Embolization Market: Growth Drivers

• Educating and Informing Men about Serious Health Issues

Men are encouraged to consult their GP in case of the slightest doubt about prostatic health. Several promotional campaigns around prostate cancer have been launched by companies such as Pfizer and Janssen. Hence, men have become more aware about rare disorders and diseases such as prostatic artery embolization.

• Advancements in Urology

Study of prostatic conditions is closely related to the domain of urology. Urologists are quick to offer their feedback on reports of screening and diagnosis tests. This factor has emerged as an important driver of demand within the global prostatic artery embolization market.

Global Prostatic Artery Embolization Market: Regional Outlook

On the basis of regions, the prostatic artery embolization market is segmented into South America, North America, Europe, the Middle East and Africa, and Asia Pacific. PAE technology was conceptualised in Brazil before clinical acceptance across the world. This factor has aided the growth of the prostatic artery embolization market in South America, and partly that of North America.

The global prostatic artery embolization market can be segmented along the following parameters:

By Type

• Type 1
• Type 2

By Application

• Men below 60
• Men aged 60-85
• Men older than 85